Jade Biosciences, Inc.

Jade Biosciences, Inc. (ticker: JBIO) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of JBIO's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. JBIO reported no tagged revenue in revenue and -$40.37M for the period ending 2026-03-31, with operating cash flow of -$24.08M. Cash and equivalents stood at $55.09M (up 24.6% year-over-year). Total assets of $319.43M exceed total liabilities of $22.97M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.